Erasca, Inc.

Erasca is a clinical-stage precision oncology company that discovers, develops, and commercializes targeted therapies for patients with cancers driven by the RAS/MAPK signaling pathway. The company’s modality-agnostic pipeline includes clinical-stage drug candidates such as ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, as well as discovery-stage assets like ERAS-12, an anti-EGFR biparatopic antibody. Its therapies address multiple signaling nodes, direct RAS mechanisms, and pathway escape routes to overcome treatment resistance. Erasca designs its product candidates for individuals diagnosed with solid tumors and other malignancies associated with RAS and MAPK pathway alterations.

Erasca conducts research and clinical development internationally, with clinical trials taking place in the United States and China. The organization licenses and acquires therapeutic candidates from multiple geographic territories through partnerships with third-party pharmaceutical entities. It also maintains Erasca Ventures, an investment subsidiary targeting early-stage biotechnology firms, and supports the Erasca Foundation, a California public benefit corporation. The provided text does not state the company's headquarters location or employee headcount.

Summary of the business section of Erasca's latest annual report, written by StockData.

“As of February 28, 2026, we had 103 full-time employees (FTEs), 34 of whom have doctorate degrees.”